Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| Therapy Name | Datopotamab Deruxtecan |
| Synonyms | |
| Therapy Description |
DS-1062a is an antibody-drug conjugate comprising an antibody that targets TROP2 linked to the topoisomerase I inhibitor DXd, which may inhibit tumor growth (J Clin Oncol 36, 2018 (suppl; abstr e24206)). |
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Datopotamab Deruxtecan | Dato-DXd|DS1062a|DS 1062a|DS-1062a | Datopotamab Deruxtecan (DS-1062a) is an antibody-drug conjugate comprising an antibody that targets TROP2 linked to the topoisomerase I inhibitor DXd, which may induce apoptosis and inhibit tumor growth (PMID: 34413126). |
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04940325 | Phase II | Datopotamab Deruxtecan | Datopotamab (DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer (ICARUS-LUNG01) | Recruiting | FRA | 0 |
| NCT05489211 | Phase II | Capecitabine + Datopotamab Deruxtecan AZD5305 + Datopotamab Deruxtecan + Durvalumab Capecitabine + Datopotamab Deruxtecan + Nivolumab Carboplatin + Datopotamab Deruxtecan Datopotamab Deruxtecan + Fluorouracil AZD5305 + Datopotamab Deruxtecan Datopotamab Deruxtecan + Durvalumab Datopotamab Deruxtecan + Fluorouracil + Nivolumab Bevacizumab + Datopotamab Deruxtecan + Fluorouracil + Leucovorin Bevacizumab + Capecitabine + Datopotamab Deruxtecan Datopotamab Deruxtecan | Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours | Recruiting | USA | ITA | FRA | ESP | DEU | CAN | 8 |
| NCT05374512 | Phase III | Eribulin Nab-paclitaxel Paclitaxel Datopotamab Deruxtecan Carboplatin Capecitabine | A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy | Recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | 16 |
| NCT04656652 | Phase III | Docetaxel Datopotamab Deruxtecan | Study of DS-1062A Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-LUNG01) | Recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | 19 |
| NCT05104866 | Phase III | Gemcitabine Capecitabine Datopotamab Deruxtecan Vinorelbine Eribulin | A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01) | Recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | 14 |
| NCT03401385 | Phase I | Datopotamab Deruxtecan | First-in-human Study of DS-1062a for Advanced Solid Tumors | Recruiting | USA | 1 |
| NCT04484142 | Phase II | Datopotamab Deruxtecan | Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05) | Active, not recruiting | USA | ITA | FRA | ESP | DEU | 5 |
CKB BOOST